Hoyland - yes I think so unless they've split sometime quite recent. There's other info online on the J&J / Calimmune link (not much - Calimmune very low profile) but here's Geoff Symond's bio below for upcoming World Gene Therapy Congress (London May 2012):
"Geoff Symonds is Chief Scientific Officer of Calimmune, a biotech start-up company with laboratories both in Australia and the USA, and a Conjoint Professor in the Faculty of Medicine at the University of New South Wales in Sydney, Australia. He has been involved in research aimed at understanding normal and abnormal hematopoiesis for three decades, including 18 years overseeing the research and development of cell-delivered HIV gene therapy at Johnson and Johnson Research that progressed to a Phase II study. As Chief Scientific Officer of Calimmune, he has, in a short span of time, guided their present lead construct through pre-clinical studies, including pilot vector manufacture and a GLP Pharm/Tox humanized mouse study for a planned IND submission in 2012. He has approximately 100 publications, several patents and a long-standing interest in the use of retroviral vectors for gene therapy."
Hoyland - yes I think so unless they've split sometime quite...
Add to My Watchlist
What is My Watchlist?